

Derivation of First-in-Class therapeutic antibody candidate for the treatment of claudin-3 overexpressing solid cancers

Abion, Inc.



ONCOLOGY	Candidate
Product Type	Fully human IgG1, afucosylated
Indication	CLDN3-positive solid tumors including NSCLC, SCLC, Breast and Ovarian cancers
Target	Claudin-3 (CLDN3)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Upon malignant transformation, tumor cells proliferate through out-of-plan division, leading to the exposure of CLDN3 to the outside of the tight junction • ABN501 specifically targets CLDN3 on tumor cell surfaces • ABN501 induces tumor cell death through cell-mediated immune response such as ADCC, ADCP, and CDC
Competitiveness	First-in-Class
Development Stage	Candidate
Route of Administration	Intravenous injection